Hemostasis is the tightly regulated process that maintains blood in a fluid state within the circulation while enabling rapid clot formation at sites of vascular injury. It involves a coordinated interplay between the vascular endothelium, platelets, coagulation factors, and the fibrinolytic system. Understanding hemostasis is fundamental to interpreting laboratory coagulation tests and diagnosing bleeding and thrombotic disorders.
Primary Hemostasis
Primary hemostasis refers to the formation of the platelet plug and occurs within seconds of vascular injury. Endothelial injury exposes subendothelial collagen and von Willebrand factor (vWF). Platelets adhere to exposed collagen via glycoprotein Ia/IIa receptors and to vWF via glycoprotein Ib (GPIb). Adhesion triggers platelet activation: shape change from discoid to spiny sphere, degranulation releasing ADP and serotonin from dense granules and fibrinogen from alpha granules, and thromboxane A₂ synthesis via cyclooxygenase (COX). Activated platelets express GPIIb/IIIa receptors that bind fibrinogen, cross-linking platelets into an aggregated plug. This primary plug is unstable and requires reinforcement by the coagulation cascade.
Secondary Hemostasis
Secondary hemostasis stabilizes the platelet plug with a fibrin mesh. The coagulation cascade is a series of serine protease zymogen activation steps culminating in thrombin generation. Thrombin converts fibrinogen to fibrin, activates factor XIII to cross-link fibrin polymers, and amplifies coagulation by activating factors V, VIII, and XI. The cascade is organized into intrinsic (contact activation), extrinsic (tissue factor), and common pathways. Laboratory assessment employs the PT and aPTT to evaluate these pathways.
Anticoagulant Mechanisms
Hemostasis is balanced by natural anticoagulant mechanisms that prevent excessive thrombosis. Antithrombin (AT) is a serine protease inhibitor that inactivates thrombin and factors Xa, IXa, XIa, and XIIa; its activity is greatly accelerated by heparin. The protein C system: thrombin binds thrombomodulin on intact endothelium, activating protein C (APC), which with protein S as cofactor inactivates factors Va and VIIIa. Tissue factor pathway inhibitor (TFPI) inhibits the tissue factor-factor VIIa complex. The endothelium produces prostacyclin (PGI₂) and nitric oxide (NO) to inhibit platelet adhesion and vasodilate.
Fibrinolysis
Fibrinolysis is the process of clot degradation that removes fibrin once vascular integrity is restored. Plasminogen is incorporated into the clot during formation and is activated to plasmin by tissue-type plasminogen activator (t-PA) from endothelium and urokinase-type plasminogen activator (u-PA). Plasmin degrades fibrin into soluble degradation products, including D-dimer — the specific cross-linked fibrin degradation product measured clinically. Fibrinolysis is regulated by plasminogen activator inhibitor-1 (PAI-1) and alpha-2-antiplasmin, which inhibit t-PA and plasmin respectively.
Laboratory Evaluation of Hemostasis
Initial screening for hemostatic disorders includes the PT/INR (extrinsic pathway), aPTT (intrinsic pathway), fibrinogen, and platelet count. Prolongation of PT, aPTT, or both guides further testing with mixing studies (1:1 mix with normal plasma) to distinguish factor deficiency from inhibitor. Specific factor assays (factors VIII, IX, XI, XII, von Willebrand factor) and platelet function tests are performed based on clinical presentation and screening results.
Bleeding Disorders
Bleeding disorders are classified by the defective phase of hemostasis. Platelet disorders (ITP, von Willebrand disease, platelet function defects) present with mucocutaneous bleeding (petechiae, ecchymoses, epistaxis, gingival bleeding, menorrhagia). Coagulation factor deficiencies (hemophilia A/factor VIII, hemophilia B/factor IX, factor XI deficiency) present with deep tissue bleeding (hemarthroses, intramuscular hematomas, intracranial hemorrhage). von Willebrand disease is the most common inherited bleeding disorder, affecting both primary (platelet adhesion) and secondary (factor VIII protection) hemostasis.
